Drug Profile


Alternative Names: AbGn-168; AbGn-168H; Antibody-168

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AbGenomics Corporation
  • Developer AbGenomics Corporation; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis; Ulcerative colitis
  • Phase I Type 1 diabetes mellitus
  • No development reported Graft-versus-host disease
  • Discontinued Plaque psoriasis

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Treatment-experienced) in USA (IV, Infusion)
  • 31 May 2018 AbGenomics initiates enrolment in a phase I trial for Graft-versus-host disease (Treatment experienced) in USA(NCT03327857)
  • 30 Apr 2018 Phase-II clinical trials in Ulcerative colitis in USA (IV) (NCT03298022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top